NORTH AMERICA DIABETES DRUGS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • NORTH AMERICA DIABETES DRUGS MARKET FORECAST 2019-2027

NORTH AMERICA DIABETES DRUGS MARKET FORECAST 2019-2027

North America is the world’s largest market for diabetes drugs and holds more than half of total market volume. In this region, the diabetes drugs market is rising due to various factors which include the rising government initiatives and investments for the diabetes drugs in the healthcare sector. The North American diabetes drug market is expected to grow at a CAGR of 4.98% during the forecast period of 2019-2027.

NORTH AMERICA DIABETES DRUGS MARKET FORECAST 2018-2026

North America Diabetes Drugs Market is segmented by Diabetes Type( Type 1, Type 2) by Product Class( Insulin (Fast Acting Insulin, Intermediate Acting Insulin, Long-acting Insulin) Non-Insulin (DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors)) & by Geography

Request free sample

North America is the world’s largest market for diabetes drugs and holds more than half of total market volume. In this region, the diabetes drugs market is rising due to various factors which include the rising government initiatives and investments for the diabetes drugs in the healthcare sector. The North American diabetes drug market is expected to grow at a CAGR of 4.98% during the forecast period of 2019-2027.

The rising prevalence of diabetes and obesity rate is anticipated to be the key factors for the growth of the diabetes drug market growth. The accessibility to therapies by reimbursement programs is further expected to result in a high turnout of patients opting for treatment, propelling the growth of the market. The U.S. is the major contributor to the success of North America’s diabetes drugs due to the presence of a major diabetes drugs delivery market. Diabetes is said to be the most expensive condition in terms of total dollars spent nationwide. Meanwhile, Canada was placed seventh globally with a diabetes-related health expenditure of $xx billion. It is mainly due to their sedentary lifestyles and unhealthy eating habits that more than half of the population is either obese or overweight. The implementation of various norms and policies for the development of anti-diabetic drugs is expected to boost market growth.

Leading market players in the North American diabetes drugs market are Xeris Pharmaceuticals, Eli Lilly And Company, Novo Nordisk A/S, B.Braun Melsungen Ag, Sanofi, Xoma Corp., Astellas Pharma, Merck, AstraZeneca Plc., Diavacs Inc., Macrogenics Inc., Albireo Pharma Inc., Pfizer and GlaxoSmithKline.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • RISING PREVALENCE OF TYPE 2 DIABETES
      • INSULIN MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • INCREASE IN PREVALENCE OF DIABETES
      • ADVANCES IN INSULIN TECHNOLOGY
      • GROWING ELDERLY POPULATION
    • MARKET RESTRAINTS
      • STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
      • LACK OF AWARENESS AMONG PEOPLE
      • COST SENSITIVITY ISSUES
    • MARKET OPPORTUNITIES
      • DEVELOPMENT OF NEW FORMULATIONS
      • INCREASING RESEARCH AND DEVELOPMENT
    • MARKET CHALLENGES
      • FIERCE MARKET COMPETITION
      • RISING CONCERNS IN SCIENTIFIC COMMUNITY
      • GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
      • POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN
  1. MARKET SEGMENTATION
    • MARKET BY DIABETES TYPE 2019-2027
      • TYPE 1
      • TYPE 2
    • MARKET BY PRODUCT CLASS 2019-2027
      • INSULIN
        • FAST ACTING INSULIN
        • INTERMEDIATE ACTING INSULIN
        • LONG-ACTING INSULIN
      • NON-INSULIN
        • DPP-4 INHIBITOR
        • GLP-1 RECEPTORS AGONISTS
        • SGLT-2 INHIBITORS
        • OTHER NON-INSULIN DRUGS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • ETYMOLOGY OF DIABETES DRUGS MARKET
    • LEGAL, POLICY AND REGULATORY ISSUES
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
  1. COMPANY PROFILES
    • ELI LILLY AND COMPANY
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ASTRAZENECA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BRAUN MELSUNGEN AG
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC ANALYSIS
    • NOVO NORDISK A/S
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SANOFI
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • DIAVACS INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • XOMA CORP.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ALBIREO PHARMA INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • MACROGENICS, INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • ASTELLAS PHARMA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GLAXOSMITHKLINE
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • MERCK
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • XERIS PHARMACEUTICALS
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES

TABLE LIST

TABLE  1      NORTH AMERICA DIABETES DRUGS MARKET  2019-2027 ($ MILLION)

TABLE  2      NORTH AMERICA DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)

TABLE  3      NORTH AMERICA DIABETES DRUGS MARKET IN TYPE 1 DIABETES  2019-2027 ($ MILLION)

TABLE  4      NORTH AMERICA DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027  ($ MILLIONS)

TABLE  5      NORTH AMERICA DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)

TABLE  6      NORTH AMERICA DIABETES DRUGS MARKET IN INSULIN TYPE  2019-2027 ($ MILLION)

TABLE  7      NORTH AMERICA DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)

TABLE  8      NORTH AMERICA INSULIN MARKET IN FAST ACTING INSULIN  2019-2027 ($ MILLION)

TABLE  9      NORTH AMERICA INSULIN MARKET IN INTERMEDIATE ACTING INSULIN  2019-2027 ($ MILLION)

TABLE  10    NORTH AMERICA INSULIN MARKET IN LONG ACTING INSULIN  2019-2027 ($ MILLION)

TABLE  11    NORTH AMERICA DIABETES DRUGS MARKET IN NON-INSULIN DRUGS  2019-2027 ($ MILLION)

TABLE  12    NORTH AMERICA DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)

TABLE  13    NORTH AMERICA NON-INSULIN DRUGS MARKET IN  DPP-4 INHIBITOR  2019-2027 ($ MILLION)

TABLE  14    NORTH AMERICA NON-INSULIN DRUGS MARKET IN  GLP-1 RECEPTORS AGONISTS  2019-2027 ($ MILLION)

TABLE  15    NORTH AMERICA NON-INSULIN DRUGS MARKET IN  SGLT-2 INHIBITORS  2019-2027 ($ MILLION)

TABLE  16    NORTH AMERICA NON-INSULIN DRUGS MARKET IN  OTHER NON-INSULIN DRUGS  2019-2027 ($ MILLION)

TABLE  17    NORTH AMERICA DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

 

FIGURE LIST

FIGURE  1    NORTH AMERICA DIABETES DRUGS MARKET 2019-2027 ($ BILLION)

FIGURE  2    NORTH AMERICA DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)

FIGURE  3    AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY GENDER (IN YEARS)

FIGURE  4    PORTER’S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET

FIGURE  5    THE UNITED STATES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  6    CANADA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

  1. MARKET SEGMENTATION
    • MARKET BY DIABETES TYPE 2019-2027
      • TYPE 1
      • TYPE 2
    • MARKET BY PRODUCT CLASS 2019-2027
      • INSULIN
        • FAST ACTING INSULIN
        • INTERMEDIATE ACTING INSULIN
        • LONG-ACTING INSULIN
      • NON-INSULIN
        • DPP-4 INHIBITOR
        • GLP-1 RECEPTORS AGONISTS
        • SGLT-2 INHIBITORS
        • OTHER NON-INSULIN DRUGS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now